9999999997-23-004516.txt : 20231010 9999999997-23-004516.hdr.sgml : 20231010 20231010170002 ACCESSION NUMBER: 9999999997-23-004516 CONFORMED SUBMISSION TYPE: SEC STAFF ACTION CATEGORY: ORDER PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20231010 ACTION DATE: 20231010 RECEIVED DATE: 20231010 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GENEREX BIOTECHNOLOGY CORP CENTRAL INDEX KEY: 0001059784 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 820490211 STATE OF INCORPORATION: DE FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: SEC STAFF ACTION BUSINESS ADDRESS: STREET 1: 10102 USA TODAY WAY CITY: MIRAMAR STATE: FL ZIP: 33025 BUSINESS PHONE: 416-364-2551 MAIL ADDRESS: STREET 1: 10102 USA TODAY WAY CITY: MIRAMAR STATE: FL ZIP: 33025 ORDER 1 filename1.pdf begin 644 filename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